Sign in / Join Now
ETFs & Funds
: Wall St completely ignoring great results of ALS and
should just buy them out. Ridiculously undervalued at $70M
Omecamtiv is a wonder drug that can be used in the ICU like water. It raises
. Too good to be true.
As a long-time ICU nurse who's seen tons of tachyarrythmia from inotropes, I agree (seems too good to be true). Interesting.
Add a reply...
Latest StockTalks »
people get CYTK breaking news and analysis by email alert.
Get email alerts on CYTK »
Get latest price
From other sites
Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results
at TheStreet (Thu, 4:00PM)
Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv
at TheStreet (Oct 18, 2016)
Cytokinetics To Announce Third Quarter Results On October 27, 2016
at TheStreet (Oct 13, 2016)
Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options
at TheStreet (Sep 30, 2016)
Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas
at TheStreet (Sep 29, 2016)